Food and Drug Administration Grants Two New Label Changes to TIROSINT®-SOL (LEVOTHYROXINE SODIUM) Oral Solution

New FDA-approved label updates offer patients more flexible administration PARSIPPANY, N.J., December 4, 2023 — The U.S. Food and Drug Administration (FDA) has approved two new changes to the label of Tirosint-SOL (levothyroxine sodium) oral solution, a unique formulation of levothyroxine (LT4) for the treatment of hypothyroidism. The first regards the use of Tirosint-SOL in Read More »